---
title: "Curis Inc. Announces Date for Upcoming Special Meeting of Stockholders"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275367398.md"
datetime: "2026-02-09T21:56:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275367398.md)
  - [en](https://longbridge.com/en/news/275367398.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275367398.md)
---

# Curis Inc. Announces Date for Upcoming Special Meeting of Stockholders

Curis Inc. will hold a Special Meeting of Stockholders virtually on March 17, 2026. At the meeting, stockholders will vote on the approval of an increase in authorized shares, the approval of the Preferred Stock Conversion and Warrant Exercise, the approval of the 2026 Incentive Plan, and the approval of the adjournment proposal. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001108205-26-000007), on February 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [CRIS.US](https://longbridge.com/en/quote/CRIS.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Danaher Corporation (NYSE:DHR) Short Interest Up 25.0% in March](https://longbridge.com/en/news/283039047.md)
- [Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)](https://longbridge.com/en/news/283014601.md)
- [BUZZ-Precision BioSciences up as hepatitis B gene‑editing trial expands in Europe](https://longbridge.com/en/news/282832865.md)
- [AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization](https://longbridge.com/en/news/283037094.md)
- [Avant Brands Reports Q1 2026 Results Highlighted by 37% Growth in Recreational Revenue | AVTBF Stock News](https://longbridge.com/en/news/282741678.md)